NIKE, Inc. filed an 8-K with the U.S. Securities and Exchange Commission on September 10, 2026, reporting the results of its annual meeting of shareholders held virtually on September 8, 2026, including director elections, an advisory vote on executive compensation, auditor ratification, and approval …
A Form 4 filed on September 10, 2026 discloses that Nike, Inc. director Peter B. Henry received a restricted stock grant of Class B Common Stock on September 8, 2026.
SunocoCorp LLC filed a Form 8-K on September 10, 2026, disclosing its voluntary withdrawal of Common Units from the New York Stock Exchange and a planned transfer of the listing to the Texas Stock Exchange.
Modine Manufacturing Company filed an 8-K on September 10, 2026, announcing it intends to rename itself Modexus Solutions following the planned spinoff of its Performance Technologies business and a merger with Gentherm, subject to shareholder approval of an amendment to its Articles of Incorporation.
Vicor Corporation filed a current report on Form 8-K on September 10, 2026, disclosing that its Board of Directors amended the company's Bylaws effective September 9, 2026, to clarify provisions relating to the removal of directors.
The Williams Companies, Inc. filed an 8-K with the SEC on September 10, 2026, disclosing the completion of a registered offering of four tranches of senior unsecured notes totaling $2.75 billion in aggregate principal amount.
Fortive Corporation filed a current report on September 10, 2026, disclosing the appointment of Susan L. Main to its Board of Directors and Audit Committee, effective September 9, 2026.
Beyond Air is a commercial-stage company built around its LungFit platform, which generates nitric oxide from ambient air. Its lead product, LungFit PH, is cleared to treat term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Over recent quarters the company …
Matinas BioPharma built its reputation on a lipid nanocrystal (LNC) delivery platform and its lead candidate MAT2203, an oral formulation of the antifungal amphotericin B aimed at serious invasive fungal infections. On July 13, 2026, the company changed course dramatically. It signed a definitive …
Eagle Pharmaceuticals historically built its portfolio around injectable and specialty hospital products, including established franchises in oncology support and critical-care medicines, alongside efforts to broaden its pipeline. The company's trajectory changed sharply in 2024, when it disclosed that it had fallen behind on required …